← All trials
NCT06651970
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2024
- Primary completion
- Aug 16, 2030
- Completion date
- Oct 9, 2030
- First posted
- Oct 22, 2024
- Last posted
- Oct 22, 2024
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AstraZenecaLead sponsor
- ERT ClinicalCollaborator
- FortreaCollaborator
- Center for Information and Study on Clinical Research Participation (CISCRP)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.